Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The characteristics of the treatment history:~  1. No sorafenib treatment history, no sorafenib allergies.~ 2. No chemotherapy, radiotherapy and transcatheter arterial chemoembolization(TACE) treatment history before surgery.~* The characteristics of the tumor:~  1. The pathological results is hepatocellular carcinoma.~ 2. Meet any of the following articles:~     * Pathological prompt microvascular invasion(MVI) class II, and incorporate any of the following:Tumor number\>3,Tumor size\>8cm,Tumor margin is not clear and no complete capsule.~    * With the embolus in Portal vein, hepatic vein or bile duct.~    * Preoperative rupture or invasion the adjacent organs.~    * The positive cut edge.~    * Residual lesions showed by Postoperative digital subtraction angiography(DSA).~    * Alpha fetoprotein(AFP) did not drop to normal range two months after surgery.~* The characteristics of the patients:~  1. The patient age was between 18-75.~ 2. The American Society of Anesthesiologists(ASA）score was I-III.~ 3. No history of esophageal varices and gastrointestinal bleeding.~ 4. The Child-pugh score was A.~ 5. Routine blood test: the leukocyte\>2.5\*10\^9, platelet\> 60\*10\^9.~ 6. The Prothrombin time was prolonged less than 2 second.~ 7. The Eastern Cooperative Oncology Group(ECOG) score was less than 2 points~Exclusion Criteria:~* Sorafenib treatment before surgery.~* Pregnant or lactating women.~* The Child-pugh score was B-C.~* Patients with other malignant tumor.~* Patients with mental illness.~* Patients participated in other clinical trials in last three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: PLACEBO_COMPARATOR): just follow up after liver resection in HCC patients
- sorafenib (Type: ACTIVE_COMPARATOR): use sorafenib after liver resection in HCC patients
- sorafenib and aspirin (Type: ACTIVE_COMPARATOR): use sorafenib and aspirin after liver resection in HCC patients

Based on this trial design, predict the completion outcome and termination type (if applicable).